Allele a of the rs16147 variant of neuropeptide Y predicts early metabolic improvements after bariatric surgery with biliopancreatic diversion in morbid obese subjects

Abstract

Background and aimsFew studies have assessed the effect of rs16147 on metabolic response after weight loss interventions. We evaluated the effect of the genetic variant rs16147 NPY gene on biochemical changes after biliopancreatic diversion surgery in morbidly obese subjects during 4 years follow up.Material and methodsOne hundred and forty seven patients with morbid obesity without diabetes mellitus type 2 were enrolled. Biochemical and anthropometric evaluation were registered before and after 1, 2, 3 and 4 years follow up. Genotype of rs16147 NPY gene has been studied.ResultsFasting glucose, insulin, HOMA-IR and lipid profile improved in both genotype groups. Although the improvement in glucose, insulin and HOMA-IR was significant in both genotypes, this change was earlier in the A allele carriers and as soon as 1 year after surgery, and we only detected the improvement at 3 years in non A allele carriers. So, basal glucose improvements the first year (non-A allele vs A allele carriers) (delta:-6.2 ± 2.1 mg/dL vs. −8.5 ± 0.8 mg/dL; p = 0.02) and the second year (delta: -9.0 ± 2.1 mg/dL vs. −15.4 ± 2.1 mg/dL; p = 0.01) were higher in A allele carriers than non-A allele carriers. The decrease of fasting insulin were better in A allele carriers the first year (delta:-2.0 ± 1.1 mUI/L vs. −4.8 ± 0.6 mUI/L; p = 0.03) and the second year (delta: -2.4 ± 0.2 mUI/L vs. −5.7 ± 0.2 mUI/L; p = 0.01). Finally, the improvement of HOMA-IR levels was earlier in A allele carriers than non-A allele carriers as reported; at year one (delta:-0.4 ± 0.2 mUI/L vs. −1.7 ± 0.2 mUI/L; p = 0.03), year two (delta: -1.1 ± 0.2 mUI/L vs. −1.8 ± 0.2 mUI/L; p = 0.02), too.ConclusionThe presence of A allele of rs16147 genetic variant produces an early metabolic response secondary to weight loss after bariatric surgery. Few studies have assessed the effect of rs16147 on metabolic response after weight loss interventions. We evaluated the effect of the genetic variant rs16147 NPY gene on biochemical changes after biliopancreatic diversion surgery in morbidly obese subjects during 4 years follow up. One hundred and forty seven patients with morbid obesity without diabetes mellitus type 2 were enrolled. Biochemical and anthropometric evaluation were registered before and after 1, 2, 3 and 4 years follow up. Genotype of rs16147 NPY gene has been studied. Fasting glucose, insulin, HOMA-IR and lipid profile improved in both genotype groups. Although the improvement in glucose, insulin and HOMA-IR was significant in both genotypes, this change was earlier in the A allele carriers and as soon as 1 year after surgery, and we only detected the improvement at 3 years in non A allele carriers. So, basal glucose improvements the first year (non-A allele vs A allele carriers) (delta:-6.2 ± 2.1 mg/dL vs. −8.5 ± 0.8 mg/dL; p = 0.02) and the second year (delta: -9.0 ± 2.1 mg/dL vs. −15.4 ± 2.1 mg/dL; p = 0.01) were higher in A allele carriers than non-A allele carriers. The decrease of fasting insulin were better in A allele carriers the first year (delta:-2.0 ± 1.1 mUI/L vs. −4.8 ± 0.6 mUI/L; p = 0.03) and the second year (delta: -2.4 ± 0.2 mUI/L vs. −5.7 ± 0.2 mUI/L; p = 0.01). Finally, the improvement of HOMA-IR levels was earlier in A allele carriers than non-A allele carriers as reported; at year one (delta:-0.4 ± 0.2 mUI/L vs. −1.7 ± 0.2 mUI/L; p = 0.03), year two (delta: -1.1 ± 0.2 mUI/L vs. −1.8 ± 0.2 mUI/L; p = 0.02), too. The presence of A allele of rs16147 genetic variant produces an early metabolic response secondary to weight loss after bariatric surgery.